HLS Therapeutics Inc.

OTCPK:HLTR.F Stock Report

Market Cap: US$86.9m

HLS Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:HLTR.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Dec 24BuyUS$1,360Norma BeauchampIndividual500US$2.72
12 Dec 24BuyUS$4,811John WelbornIndividual2,100US$2.29
14 Nov 24SellUS$1,181Norma BeauchampIndividual500US$2.36
14 Aug 24BuyUS$9,300John HannaIndividual4,000US$2.33
15 May 24BuyUS$7,250Craig MillianIndividual2,500US$2.90

Insider Trading Volume

Insider Buying: HLTR.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HLTR.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders173,2650.545%
Institutions6,729,49921.2%
Hedge Funds12,331,92438.8%
General Public12,558,35939.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 17 shareholders own 60.5% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20%
Polar Asset Management Partners Inc.
6,367,082US$17.4m0%0.64%
18.8%
Stadium Capital Management, LLC
5,964,842US$16.3m0%9.26%
10.2%
Mawer Investment Management Ltd.
3,237,056US$8.9m0%0.02%
9.6%
Neuberger Berman Investment Advisers LLC
3,051,782US$8.3m0%0.01%
0.78%
Rbc Indigo Asset Management Inc
247,745US$677.5k0%0.02%
0.31%
John Welborn
99,100US$271.0k2.16%no data
0.31%
ATB Investment Management Inc.
97,211US$265.8k0%no data
0.18%
Dimensional Fund Advisors LP
58,360US$159.6k-0.01%no data
0.16%
Jason Gross
49,700US$135.9k0%no data
0.085%
Manulife Asset Management
27,000US$73.8k0%no data
0.039%
Craig Millian
12,500US$34.2k0%no data
0.033%
Highland Capital Management, L.P.
10,445US$28.6k0%0.01%
0.025%
John Hanna
8,000US$21.9k100%no data
0.0056%
Kyle Dempsey
1,765US$4.8k0%no data
0.0038%
Brian Walsh
1,200US$3.3k0%no data
0.0016%
Norma Beauchamp
500US$1.4k0%no data
0.0016%
Ryan Lennox
500US$1.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:18
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
George UlybyshevClarus Securities Inc.